- Home
- CYH vs EYPT Comparison
CYH vs EYPT Comparison
Compare CYH & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYH
- EYPT
- Stock Information
- Founded
- CYH 1985
- EYPT 1987
- Country
- CYH United States
- EYPT United States
- Employees
- CYH N/A
- EYPT N/A
- Industry
- CYH Hospital/Nursing Management
- EYPT Biotechnology: Laboratory Analytical Instruments
- Sector
- CYH Health Care
- EYPT Industrials
- Exchange
- CYH Nasdaq
- EYPT Nasdaq
- Market Cap
- CYH 482.7M
- EYPT 579.4M
- IPO Year
- CYH 1991
- EYPT 2005
- Fundamental
- Price
- CYH $3.33
- EYPT $9.48
- Analyst Decision
- CYH Hold
- EYPT Strong Buy
- Analyst Count
- CYH 8
- EYPT 8
- Target Price
- CYH $4.27
- EYPT $24.75
- AVG Volume (30 Days)
- CYH 2.4M
- EYPT 821.1K
- Earning Date
- CYH 07-23-2025
- EYPT 08-06-2025
- Dividend Yield
- CYH N/A
- EYPT N/A
- EPS Growth
- CYH N/A
- EYPT N/A
- EPS
- CYH N/A
- EYPT N/A
- Revenue
- CYH $12,653,000,000.00
- EYPT $56,042,000.00
- Revenue This Year
- CYH N/A
- EYPT N/A
- Revenue Next Year
- CYH $3.49
- EYPT N/A
- P/E Ratio
- CYH N/A
- EYPT N/A
- Revenue Growth
- CYH 1.05
- EYPT 12.04
- 52 Week Low
- CYH $2.24
- EYPT $3.91
- 52 Week High
- CYH $6.29
- EYPT $13.99
- Technical
- Relative Strength Index (RSI)
- CYH 51.63
- EYPT 72.76
- Support Level
- CYH $3.28
- EYPT $7.94
- Resistance Level
- CYH $3.56
- EYPT $10.77
- Average True Range (ATR)
- CYH 0.20
- EYPT 0.74
- MACD
- CYH -0.02
- EYPT 0.10
- Stochastic Oscillator
- CYH 50.00
- EYPT 85.87
About CYH Community Health Systems Inc.
Community Health Systems Inc is a publicly owned hospital operator in the United States. The company also owns four home health agencies and provides management and consulting services to independent hospitals. The firm derives revenue through a broad range of general and specialized hospital healthcare services and outpatient services.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.